The Evaluation of the Overexpression of the ERG-11, MDR-1, CDR-1, and CDR-2 Genes in Fluconazole-resistant Candida Albicans Isolated from Ahvazian Cancer Patients with Oral Candidiasis

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2022 Jan 8

PMID 34997991

Citations 7

Authors

Mehrnoush Maheronnaghsh

Ali Teimoori

Parvin Dehghan

Mahnaz Fatahinia

Affiliations

Soon will be listed here.

Abstract

Introduction: Resistance to azole drugs has been observed in candidiasis due to their long-term use and poor response to treatment. Resistance to azole drugs in Candida albicans isolates is controlled by several genes including ERG11, CDR1, CDR2, and MDR1. In this study, the expression of the mentioned genes was evaluated in C. albicans isolates susceptible and resistant to fluconazole.

Methods: After identifying the Candida isolates using morphological and molecular methods, the minimum inhibitory concentration (MIC) and drug susceptibility were determined using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) method. RNA was then extracted and cDNA was synthesized from 24 C. albicans isolates from patients with cancer. Then, the mean expressions of these genes were compared in two groups using real-time polymerase chain reaction (RT-PCR).

Results: A total of 74 Candida isolates were obtained from the oral cavity of 61 cancer patients with oral candidiasis. After 24 h, 21.6% of the isolates were fluconazole-resistant, 10.8% were identified as dose-dependent, and the rest of the isolates (67.6%) were fluconazole-sensitive. The mean expressions of the CDR1 and MDR1 genes were significantly higher in the resistant isolates than in the sensitive ones. However, the ERG11 and CDR2 genes were not significantly increased in the resistant isolates.

Conclusion: The increased mean expressions of the CDR1 and MDR1 genes had a greater effect on fluconazole resistance among the drug-resistant strains of C. albicans in chemotherapy patients. It seemed that the accumulation of chemotherapeutic drugs in this organism stimulated some regulatory factors and increased the expression of these two genes and ultimately helped to further increase their expression and resistance to fluconazole.

Citing Articles

Molecular Evaluation of the mRNA Expression of the , , , and Genes Linked to Fluconazole Resistance in in a Colombian Population.

Cardenas Parra L, Rojas Rodriguez A, Perez Cardenas J, Perez-Agudelo J J Fungi (Basel). 2024; 10(7).

PMID: 39057394 PMC: 11277825. DOI: 10.3390/jof10070509.

Mechanism and bioinformatics analysis of the effect of berberine-enhanced fluconazole against drug-resistant Candida albicans.

Wu S, Jia W, Lu Y, Jiang H, Huang C, Tang S BMC Microbiol. 2024; 24(1):196.

PMID: 38849761 PMC: 11157861. DOI: 10.1186/s12866-024-03334-0.

Exploring the Biofilm Inhibition Potential of a Novel Phytic Acid-Crosslinked Chitosan Nanoparticle: In Vitro and In Vivo Investigations.

Nayak R, Rai V, Pradhan D, Halder J, Rajwar T, Dash P AAPS PharmSciTech. 2024; 25(5):106.

PMID: 38724834 DOI: 10.1208/s12249-024-02829-3.

Synthesis of new imidazole-based ionic liquids with antifungal activity against .

Habibi A, Bayat M, Omidi B, Ezabadi A, Mortazavi P Iran J Microbiol. 2023; 15(6):811-820.

PMID: 38156299 PMC: 10751616. DOI: 10.18502/ijm.v15i6.14162.

Effect of new methionine-based ionic liquid on the and gene expression on sensitive and resistant strains of .

Eslami M, Ezabadi A, Bayat M, Omidi B, Mortazavi P Iran J Microbiol. 2023; 15(2):325-335.

PMID: 37193238 PMC: 10183073. DOI: 10.18502/ijm.v15i2.12485.

References

Nakamura K, Niimi M, Niimi K, Holmes A, Yates J, Decottignies A . Functional expression of Candida albicans drug efflux pump Cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters. Antimicrob Agents Chemother. 2001; 45(12):3366-74. PMC: 90839. DOI: 10.1128/AAC.45.12.3366-3374.2001. View

White T, Holleman S, Dy F, Mirels L, Stevens D . Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2002; 46(6):1704-13. PMC: 127245. DOI: 10.1128/AAC.46.6.1704-1713.2002. View

. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect. 2008; 14(4):398-405. DOI: 10.1111/j.1469-0691.2007.01935.x. View

Schillig R, Morschhauser J . Analysis of a fungus-specific transcription factor family, the Candida albicans zinc cluster proteins, by artificial activation. Mol Microbiol. 2013; 89(5):1003-17. DOI: 10.1111/mmi.12327. View

Repp K, Menor S, Pettit R . Microplate Alamar blue assay for susceptibility testing of Candida albicans biofilms. Med Mycol. 2007; 45(7):603-7. DOI: 10.1080/13693780701581458. View

Al-Abeid H, Abu-Elteen K, Elkarmi A, Hamad M . Isolation and characterization of Candida spp. in Jordanian cancer patients: prevalence, pathogenic determinants, and antifungal sensitivity. Jpn J Infect Dis. 2004; 57(6):279-84. View

Maheronnaghsh M, Teimoori A, Dehghan P, Fatahinia M . The evaluation of the overexpression of the ERG-11, MDR-1, CDR-1, and CDR-2 genes in fluconazole-resistant Candida albicans isolated from Ahvazian cancer patients with oral candidiasis. J Clin Lab Anal. 2022; 36(2):e24208. PMC: 8842164. DOI: 10.1002/jcla.24208. View

Butts A, Reitler P, Ge W, Fortwendel J, Palmer G . Commonly Used Oncology Drugs Decrease Antifungal Effectiveness against Candida and Aspergillus Species. Antimicrob Agents Chemother. 2018; 62(7). PMC: 6021626. DOI: 10.1128/AAC.00504-18. View

Ribeiro M, Paula C . Up-regulation of ERG11 gene among fluconazole-resistant Candida albicans generated in vitro: is there any clinical implication?. Diagn Microbiol Infect Dis. 2006; 57(1):71-5. DOI: 10.1016/j.diagmicrobio.2006.04.019. View

10.

Park S, Perlin D . Establishing surrogate markers for fluconazole resistance in Candida albicans. Microb Drug Resist. 2005; 11(3):232-8. DOI: 10.1089/mdr.2005.11.232. View

11.

Schelenz S, Abdallah S, Gray G, Stubbings H, Gow I, Baker P . Epidemiology of oral yeast colonization and infection in patients with hematological malignancies, head neck and solid tumors. J Oral Pathol Med. 2010; 40(1):83-9. DOI: 10.1111/j.1600-0714.2010.00937.x. View

12.

Thakur J, Arthanari H, Yang F, Pan S, Fan X, Breger J . A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature. 2008; 452(7187):604-9. DOI: 10.1038/nature06836. View

13.

Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P, Luyten W . Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology (Reading). 1999; 145 ( Pt 10):2701-2713. DOI: 10.1099/00221287-145-10-2701. View

14.

Kauffman C . Candiduria. Clin Infect Dis. 2005; 41 Suppl 6:S371-6. DOI: 10.1086/430918. View

15.

Tsao S, Rahkhoodaee F, Raymond M . Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob Agents Chemother. 2009; 53(4):1344-52. PMC: 2663127. DOI: 10.1128/AAC.00926-08. View

16.

Mogavero S, Tavanti A, Senesi S, Rogers P, Morschhauser J . Differential requirement of the transcription factor Mcm1 for activation of the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and Cap1. Antimicrob Agents Chemother. 2011; 55(5):2061-6. PMC: 3088249. DOI: 10.1128/AAC.01467-10. View

17.

Perea S, Lopez-Ribot J, Kirkpatrick W, McAtee R, Santillan R, Martinez M . Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2001; 45(10):2676-84. PMC: 90716. DOI: 10.1128/AAC.45.10.2676-2684.2001. View

18.

Rodrigues C, Silva S, Henriques M . Candida glabrata: a review of its features and resistance. Eur J Clin Microbiol Infect Dis. 2013; 33(5):673-88. DOI: 10.1007/s10096-013-2009-3. View

19.

Goldman G, da Silva Ferreira M, Marques E, Savoldi M, Perlin D, Park S . Evaluation of fluconazole resistance mechanisms in candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis. 2004; 50(1):25-32. DOI: 10.1016/j.diagmicrobio.2004.04.009. View

20.

Morschhauser J, Barker K, Liu T, BlaB-Warmuth J, Homayouni R, Rogers P . The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 2007; 3(11):e164. PMC: 2048531. DOI: 10.1371/journal.ppat.0030164. View